# Taysha Gene Therapies *

**Canonical:** https://apis.io/providers/taysha-gene-therapies/  
**Website:** https://tayshagtx.com  
**APIs profiled:** 0

Taysha Gene Therapies is a clinical-stage biotechnology company (Dallas, TX with a laboratory in Morrisville, NC) developing AAV-based gene therapies for rare monogenic diseases of the central nervous system. Its lead program, TSHA-102, targets Rett syndrome and has completed dosing in the REVEAL pivotal trial. The company operates as a therapeutics developer and publishes no public developer API, documentation portal, or technical integration surface; it was surfaced as a GV portfolio company and added to the API Evangelist network as an enrichment lead.

## Kin Score — 3.3 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 3.3).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Taysha Gene Therapies Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Life Sciences, Biotechnology, Gene Therapy, Rare Disease, Central Nervous System, Clinical Stage, Pharmaceuticals

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/taysha-gene-therapies/). Scores are computed from the provider's own public artifacts under a published rubric.